- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | AZN |
|---|---|---|
| Founded | 1852 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7B | 250.7B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | WFC | AZN |
|---|---|---|
| Price | $82.55 | $171.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 12 |
| Target Price | $97.48 | ★ $207.16 |
| AVG Volume (30 Days) | ★ 11.9M | 2.4M |
| Earning Date | 10-13-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.41% | 1.87% |
| EPS Growth | ★ 16.57 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | ★ $85,063,000,000.00 | N/A |
| Revenue This Year | $5.34 | $7.94 |
| Revenue Next Year | $5.42 | $6.26 |
| P/E Ratio | ★ $23.09 | $31.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $72.78 | $80.48 |
| 52 Week High | $97.76 | $212.71 |
Technical Indicators
Market Signals| Indicator | WFC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 62.32 |
| Support Level | $77.95 | $154.70 |
| Resistance Level | $82.66 | $175.04 |
| Average True Range (ATR) | 1.94 | 3.14 |
| MACD | 0.30 | 1.44 |
| Stochastic Oscillator | 67.41 | 87.44 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is a premier, North American-focused banking titan that commands a $2.3 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,079 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.